160 results on '"Palumbo, Raffaella"'
Search Results
2. Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study
3. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
4. Laryngeal adenoid cystic carcinoma: Radical or conservative surgery?
5. Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
6. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
7. Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials
8. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
9. Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study
10. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series
11. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study
12. The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
13. Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials
14. Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
15. Penile Metastases From Bladder and Prostate Cancer Detected by PET/CT: A Report of 3 Cases and a Review of Literature
16. Additional file 2 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
17. Additional file 1 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
18. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
19. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin
20. Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy)
21. EFFECT: A randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
22. Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
23. Weekly Trastuzumab (Herceptin) and vinorelbine (Navelbine) in chemonaive patients with HER2-overexpressing metastatic breast cancer: A phase II trial
24. IMPACT OF ADJUVANT CHEMOTHERAPY ON OUTCOME AND SURVIVAL OF PATIENTS WITH RADICALLY RESECTED GASTRIC CANCER: LONG TERM FOLLOW-UP OF A MONOINSTITUTIONAL EXPERIENCE.
25. DOES PRIMARY MALE BREAST CANCER CARRY A WORSE PROGNOSIS COMPARED TO FEMALE? A SINGLE-CENTRE EXPERIENCE
26. OUTPATIENT INTEGRATED PHYSICO-FUNCTIONAL AND PSYCHOSOCIAL REHABILITATIVE TREATMENT AFTER PRIMARY THERAPY FOR BREAST AND HEAD & NECK CANCER: FINAL RESULTS ON 280 PATIENTS.
27. MMM (MITOMYCIN/MITOXANTRONE/METHOTREXATE) IN ADVANCED BREAST CANCER: AN "OLD" REGIMEN WITH GOOD ACTIVITY AGAINST LIVER METASTASES.
28. PHASE II STUDY OF A TEN-DAY SCHEDULE SINGLE AGENT VINORELBINE (VNR) IN ADVANCED, PRETREATED BREAST CANCER (BC): AN ACTIVE AND FEASIBLE REGIMEN.
29. Phase II study of vinorelbine (VNR), gemcitabine (GEM) and carboplatin (CBDCA) as first-line chemotherapy against brain metastases from non-small-cell lung cancer (NSCLC).
30. INTEGRATED REHABILITATION PROGRAM FOR ADULT PATIENTS WITH CANCER: ANALYSIS OF 1-YEAR EXPERIENCE.
31. PATHOLOGICAL FRACTURES THROUGH METASTASES FROM SOLID TUMORS: THE ROLE OF POST-OPERATIVE REHABILITATION PROGRAM IN PATIENT MANAGEMENT.
32. CARBOPLATIN PLUS ETOPOSIDE IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): A TOLERABLE AND ACTIVE OUTPATIENT REGIMEN.
33. FEASIBILITY AND ACTIVITY OF PRIMARY CHEMO-THERAPY WITH VINORELBINE (VNR), GEMCITABINE (GEM) AND CARBOPLATIN (CBDCA) IN BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY.
34. Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)
35. Palbociclib in metastatic breast cancer: current evidence and real-life data
36. Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
37. 18F-Fluoride PET/CT in the detection of bone metastases in clear cell renal cell carcinoma: discordance with bone scintigraphy
38. Additional file 1: of Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01â 2014)
39. Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
40. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
41. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
42. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
43. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
44. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant
45. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
46. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study
47. Does agent sequencing matter across multiple lines of chemotherapy in metastatic breast cancer (MBC)?: A single institution retrospective analysis of 550 women.
48. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
49. Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT
50. Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.